Every filing, one decision per row.

Transactions

One row for every decision an insider filed. Open-market buying and selling only. Vesting, grants and the shares withheld to pay the tax on them are not decisions.

Company: GNLX Minimum: $100K

Company

Date

Insider

Role

Action ?

Shares

Amount

Of holding

GNLX GENELUX Corp

30 Aug 2024

10% owner indirect

Sold at will

142,589

$309.85K

15.4%

GNLX GENELUX Corp

29 Aug 2024

10% owner indirect

Sold at will

107,045

$211.96K

10.4%

GNLX GENELUX Corp

27 Aug 2024

10% owner indirect

Sold at will

51,630

$108.86K

4.7%

GNLX GENELUX Corp

1 May 2024

10% owner indirect

Sold at will

33,061

$109.16K

2.7%

GNLX GENELUX Corp

16 Apr 2024

10% owner indirect

Sold at will

48,683

$171.80K

3.5%

GNLX GENELUX Corp

15 Dec 2023

VP, Clinical Trial Operations

Sold at will 2×

32,535

$428.18K

100%

GNLX GENELUX Corp

13 Dec 2023

Director

Sold at will 2×

9,000

$120.39K

1.9%

GNLX GENELUX Corp

13 Dec 2023

Director

Sold at will 2×

9,000

$118.97K

72.2%

GNLX GENELUX Corp

7 Dec 2023

VP, Clinical Trial Operations

Sold at will

36,800

$436.00K

53.1%

GNLX GENELUX Corp

21 Nov 2023

VP, Clinical Trial Operations

Sold at will

18,665

$191.56K

21.2%

GNLX GENELUX Corp

20 Nov 2023

VP, Clinical Trial Operations

Sold at will

14,594

$164.26K

14.2%

GNLX GENELUX Corp

25 Oct 2023

10% owner indirect

Sold at will

5,704

$110.64K

0.4%

GNLX GENELUX Corp

23 Oct 2023

10% owner indirect

Sold at will

49,987

$998.37K

3.5%

GNLX GENELUX Corp

10 Oct 2023

VP, Clinical Trial Operations

Sold at will 2×

5,200

$114.46K

4.7%

GNLX GENELUX Corp

5 Oct 2023

10% owner indirect

Sold at will 2×

14,251

$355.23K

1.0%

GNLX GENELUX Corp

3 Oct 2023

10% owner indirect

Sold at will

75,690

$1.93M

5.0%

GNLX GENELUX Corp

27 Sep 2023

10% owner indirect

Sold at will

11,257

$275.46K

0.7%

GNLX GENELUX Corp

26 Sep 2023

10% owner indirect

Sold at will 3×

29,805

$709.18K

1.9%

GNLX GENELUX Corp

26 Sep 2023

VP, Clinical Trial Operations

Sold at will 3×

5,200

$122.53K

4.7%

GNLX GENELUX Corp

25 Sep 2023

10% owner indirect

Sold at will 4×

12,458

$321.00K

0.8%

GNLX GENELUX Corp

22 Sep 2023

10% owner indirect

Sold at will 2×

9,042

$247.12K

0.6%

GNLX GENELUX Corp

21 Sep 2023

10% owner indirect

Sold at will 2×

7,549

$214.88K

0.5%

GNLX GENELUX Corp

20 Sep 2023

General Counsel

Sold at will

10,000

$300.00K

94.6%

GNLX GENELUX Corp

20 Sep 2023

VP, Clinical Trial Operations

Sold at will

6,000

$167.79K

5.4%

GNLX GENELUX Corp

19 Sep 2023

10% owner

Sold at will 2×

32,167

$850.94K

100%

GNLX GENELUX Corp

18 Sep 2023

10% owner indirect

Sold at will 2×

30,292

$705.65K

85.8%

GNLX GENELUX Corp

15 Sep 2023

VP, Clinical Trial Operations

Sold at will 2×

10,400

$227.63K

8.9%

GNLX GENELUX Corp

14 Sep 2023

10% owner indirect

Sold at will 2×

25,276

$557.81K

41.7%

GNLX GENELUX Corp

13 Sep 2023

VP, Clinical Trial Operations

Sold at will

29,800

$629.93K

21.9%

GNLX GENELUX Corp

13 Sep 2023

10% owner indirect

Sold at will 2×

19,032

$408.09K

23.9%

GNLX GENELUX Corp

12 Sep 2023

10% owner indirect

Sold at will 2×

20,265

$451.17K

20.3%

GNLX GENELUX Corp

11 Sep 2023

10% owner indirect

Sold at will 2×

32,351

$718.70K

24.5%

GNLX GENELUX Corp

8 Sep 2023

10% owner indirect

Sold at will 3×

24,831

$575.33K

15.8%

GNLX GENELUX Corp

7 Sep 2023

10% owner indirect

Sold at will 2×

12,446

$303.27K

7.3%

GNLX GENELUX Corp

30 Aug 2023

VP, Clinical Trial Operations

Sold at will

19,800

$489.06K

12.7%

GNLX GENELUX Corp

18 Aug 2023

Zindrick Thomas

President and CEO

Sold at will

8,349

$198.12K

36.3%

Showing 1–36 of 36.